Skip to content

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting OPS

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting OPS

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting OPS

About Us
Investors
Pipeline
Clinical Trials
Conversations
Contracting OPS

Press Releases

Select Year
Search

Found 145 Results

October 2, 2024

Cognition Therapeutics Will Participate in the Roth Healthcare Opportunities Conference

October 1, 2024

Cognition Therapeutics Supports Lewy Body Dementia Awareness Month and the Need for Improved Treatments for the Second Most Common Dementia

September 3, 2024

Cognition Therapeutics to Participate in Upcoming September 2024 Investor Conferences

August 22, 2024

Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease

August 8, 2024

Cognition Therapeutics Reports Financial Results for the Second Quarter 2024 and Provides Business and Clinical Update

August 5, 2024

Cognition Therapeutics to Report Second Quarter 2024 Financial Results

July 29, 2024

Cognition Therapeutics’ Proof-of-Concept Phase 2 SHINE Trial Demonstrates Consistent Improvement in Cognitive Outcomes with Once-Daily Oral CT1812 in Mild-to-Moderate Alzheimer’s Patients

«...2 345 6...10 20...»

Investor Relations Contact

Cognition Therapeutics
info@cogrx.com

Mikey Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Email Alerts

Email

SEC Filings

Press Releases

End of Day Stock Quote

I accept the Privacy Policy

Loading...

Linkedin-in X-twitter

Terms of Use
Privacy Policy
Careers

FCOI Policy
Contact us

Copyright© 2024 Cognition Therapeutics All rights reserved

Scroll to Top